Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
04 February 2022Website:
http://www.arcellx.comNext earnings report:
13 November 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | 3 min agoDividend
Analysts recommendations
Institutional Ownership
ACLX Latest News
Arcellx leverages proprietary platforms like D-Domain, ddCAR, and ARC-SparX to enhance immune response, targeting multiple myeloma, AML, MDS, and solid tumors. ACLX's lead therapy, anito-cel, shows strong clinical results in relapsed/refractory multiple myeloma, even for high-risk patients. Arcellx's strategic partnership with Kite Pharma validates its technology, potentially leading to milestone payments of up to $935 million.
Arcellx, Inc. (ACLX) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to loss of $0.50 per share a year ago.
The biotech industry has fallen on hard times over the last few years, no thanks to venture capital drying up, tighter regulatory conditions and the harsh reality of the post-pandemic healthcare environment. As a result, biotech breakthrough stocks fell out of favor with investors and were among the worst performers in the stock market.
Arcellx (ACLX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Arcellx, Inc. (ACLX) came out with quarterly earnings of $0.42 per share, beating the Zacks Consensus Estimate of a loss of $0.63 per share. This compares to loss of $0.76 per share a year ago.
Following a hot year of M&A with biotech stocks, we'll see more of the same in 2024 as drug makers look to build their pipelines ahead of a massive patent cliff. Between now and 2028, pharmaceutical giants stand to lose billions in revenue as blockbuster drug patents expire.
Biotech stocks, and the sector in general, saw a widespread beat down over the past two years. Venture capital dried up, post-pandemic healthcare landscapes shifted, and regulatory clampdowns tightened already-slim margins.
The pharma stock leaders can at times seem overly risk averse with their approach to developing new medicines and cures. With the difficulty of clinical trials and the uncertainty of Federal Drug Administration (FDA) approval, many pharma companies prefer to play it safe rather than bet big.
In the dynamic realm of modern medicine, biotech stocks have effectively emerged at the forefront of a transformation. These innovative players are steering us towards a new era of medical marvels with precision and personalization.
Arcellx (ACLX) and Gilead (GILD) expand their existing collaboration in cancer treatment. This deal is expected to close by year-end.
- 1(current)
What type of business is Arcellx?
Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
What sector is Arcellx in?
Arcellx is in the Healthcare sector
What industry is Arcellx in?
Arcellx is in the Biotechnology industry
What country is Arcellx from?
Arcellx is headquartered in United States
When did Arcellx go public?
Arcellx initial public offering (IPO) was on 04 February 2022
What is Arcellx website?
https://www.arcellx.com
Is Arcellx in the S&P 500?
No, Arcellx is not included in the S&P 500 index
Is Arcellx in the NASDAQ 100?
No, Arcellx is not included in the NASDAQ 100 index
Is Arcellx in the Dow Jones?
No, Arcellx is not included in the Dow Jones index
When was Arcellx the previous earnings report?
No data
When does Arcellx earnings report?
The next expected earnings date for Arcellx is 13 November 2024